Skip to main content

Efficacy and safety of adjuvant glucocorticoid therapy for Pneumocystis pneumonia (PCP) in patients positive for HIV: a systematic review and meta-analysis

In brief

Glucocorticoids cut death odds by 59% in HIV-positive patients with PCP

In a review of nine articles covering 13 studies, adding glucocorticoids was linked to lower mortality, early deterioration and need for mechanical ventilation among HIV-positive patients with Pneumocystis pneumonia. Reported adverse effects did not differ significantly from control treatment, but the review does not establish which patients benefit most or how results vary across treatment settings.

Journal
Frontiers in pharmacology (Q1)
Published
28 October 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Zhiyong Tang, Rui Li, Xiaoying Chen, Qiang Su, Bin Han, Ming Yang
PMID
43017473
DOI
10.3389/fphar.2026.1916907

Why clinicians should know about it

Abstract

OBJECTIVE: To systematically evaluate the efficacy and safety of glucocorticoids as adjuvant therapy for Pneumocystis pneumonia (PCP) in patients positive for human immunodeficiency virus (HIV). METHODS: Clinical randomized controlled trials or clinical controlled trials evaluating the efficacy and safety of glucocorticoids as adjuvant therapy for PCP in patients who are HIV-positive were retrieved from PubMed, Embase, Web of Science, and the Cochrane Library. Data extraction and methodological quality assessment were performed for eligible studies. Meta-analysis and systematic evaluation were conducted using RevMan v.5.1 and STATA v.12.0 software. RESULTS: Nine articles (13 studies) were included. Compared with the controls, patients treated with glucocorticoids had significantly lower mortality rates (OR = 0.41, 95% CI [0.28-0.59], P < 0.00001), early deterioration rates (OR = 0.08, 95% CI [0.02-0.39], P = 0.002), and lower mechanical ventilation rates (OR = 0.32, 95% CI [0.19-0.55], P < 0.0001). Regarding safety, the incidence of adverse effects did not differ significantly between the two groups (OR = 0.74, 95% CI [0.33-1.70], P = 0.48). CONCLUSION: Adjuvant glucocorticoid therapy significantly reduces mortality, early deterioration, and mechanical ventilation rates in patients who are HIV-positive with PCP without increasing adverse reactions. Glucocorticoids may serve as a viable adjuvant treatment option for PCP in patients who are HIV-positive. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/home, identifier CRD420261418795.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.